News
LPCN
5.25
+2.36%
0.12
Weekly Report: what happened at LPCN last week (0318-0322)?
Weekly Report · 3d ago
Weekly Report: what happened at LPCN last week (0311-0315)?
Weekly Report · 03/18 09:38
12 Health Care Stocks Moving In Wednesday's After-Market Session
Molina Healthcare (NYSE:MOH) stock moved upwards by 24.2% to $503.11 during Wednesday's after-market session. The company's market cap stands at $29.3 billion. Evoke Pharma (NASDAQ:EVOK) shares rose 18.54% and Aptorum Gr stock rose 11.75% during the session. Losers Spruce Biosciences and Bright Green stock declined by 75.2%.
Benzinga · 03/13 21:32
Weekly Report: what happened at LPCN last week (0304-0308)?
Weekly Report · 03/11 09:37
LPCN Stock Earnings: Lipocine Beats EPS for Q4 2023
Lipocine reported earnings per share of -42 cents. The company reported revenue of $216,188. Lipocine was above the analyst estimate for EPS of -47 cents. The company's stock was down 2% after the market closed on Wednesday.
Investorplace · 03/07 19:52
Lipocine GAAP EPS of -$3.14
Seeking Alpha · 03/07 16:17
Press Release: Lipocine Announces Financial Results for the Full Year Ended December 31, 2023
Lipocine Announces Financial Results for the Full Year Ended December 31, 2023 and provides a corporate update. Lipocine is a biopharmaceutical company focused on treating Central Nervous System disorders. The company announced positive results from a pilot study of LPCN 1154 for postpartum depression.
Dow Jones · 03/07 13:00
Press Release: Lipocine Announces Financial -2-
This release contains "forward-looking statements" about Lipocine's product development efforts. These statements involve risks and uncertainties. The company may not be successful in developing product candidates to treat CNS disorders. The FDA will not approve any of our products, and Lipocin's products are not expected to be approved.
Dow Jones · 03/07 13:00
Lipocine Inc <LPCN.OQ> expected to post a loss of 47 cents a share - Earnings Preview
Lipocine Inc expected to post a loss of 47 cents a share. The one available analyst rating on the shares is "strong buy" The company is expected to show change in quarterly revenue when it reports results on March 8. LSEG's mean analyst estimate for Lipocine is for a loss of 47 cents per share.
Reuters · 03/06 13:41
Weekly Report: what happened at LPCN last week (0226-0301)?
Weekly Report · 03/04 09:38
Weekly Report: what happened at LPCN last week (0219-0223)?
Weekly Report · 02/26 09:41
Weekly Report: what happened at LPCN last week (0212-0216)?
Weekly Report · 02/19 09:42
Lipocine Announces Key Study Dosing for Postpartum Depression Treatment
TipRanks · 02/12 21:24
Weekly Report: what happened at LPCN last week (0205-0209)?
Weekly Report · 02/12 09:38
Lipocine Announces Confirmation Of Dosing Regimen For Pivotal Study Of LPCN 1154
Positive clinical study results confirm 48-hour dosing regimen for the pivotal PK study On track for Q2-24 pivotal study topline results and planned Q4-24 NDA filing. LPCN 1154 is an oral neurosteroid being developed by Lipocine for the treatment of postpartum depression.
Benzinga · 02/06 13:02
Weekly Report: what happened at LPCN last week (0129-0202)?
Weekly Report · 02/05 09:41
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Elevai Labs (NASDAQ:ELAB) stock is rocketing more than 76% alongside heavy pre-market trading. A private placement, direct listing, earnings reports, a public offering and more are moving stocks this morning. Check out the biggest pre- market stock movers for Thursday morning.
Investorplace · 02/01 12:38
Weekly Report: what happened at LPCN last week (0122-0126)?
Weekly Report · 01/29 09:38
Weekly Report: what happened at LPCN last week (0115-0119)?
Weekly Report · 01/22 09:39
Lipocine Strikes Major Deal for TLANDO Franchise Rights
TipRanks · 01/19 08:09
More
Webull provides a variety of real-time LPCN stock news. You can receive the latest news about Lipocine Inc through multiple platforms. This information may help you make smarter investment decisions.
About LPCN
Lipocine Inc. is a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery to develop differentiated products for Central Nervous System (CNS) disorders. Its clinical development candidates include: LPCN 1154, oral brexanolone, for treatment of postpartum depression, LPCN 2101 for epilepsy, LPCN 2203 for essential tremor and LPCN 1148, a novel androgen receptor agonist prodrug for oral administration targeted for the management of symptoms associated with liver cirrhosis. It is exploring partnering opportunities for LPCN 1107, for prevention of preterm birth, LPCN1154, for rapid relief of postpartum depression, LPCN 1148, for the management of decompensated cirrhosis, and LPCN 1144, for treatment of non-cirrhotic NASH. Its product candidate, TLANDO, an oral treatment indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone.